Country: Study 1: 186 centers in 14 countries
Setting/Design: Double-blind tiotropium 18 μg+Indacaterol 150 μg once daily vs. tiotropium 18 μg+placebo with tiotropium alone: a randomised, double-blind comparison
Time frame: 12-week study
Randomization method: An automated interactive voice response system and was stratified by COPD severity
Allocation concealment: Yes (An automated interactive voice response system)
Blinding: The blinding of indacaterol and placebo continued until the study
*   \- Participants: Yes
*   \- Investigators: Yes
*   \- Outcome assessors: Yes
Intention-to-treat: Yes
Follow-up period: 12-week
Loss to follow-up: 29/572 for indacaterol+tiotropium, 37/570 for tiotropium+placebo group

| ITT anlaysis | Indacaterol+tiotropium | Placebo+tiotropium |
| :------------------------------ | :--------------------- | :----------------- |
| Number | 572 | 570 |
| Age | 63.1±8,83 | 62.84±8,98 |
| Sex (M) | 63% | 68% |
| Ethnicity (Caucasian) | 77.8% | 79.3% |
| FEV₁ %predicted (postBD*) | 48.6 (9,74) | 48.6 (9,76) |
| FEV₁/FVC (postBD*) | 47.0 (10,21) | 47.2 (9,53) |
| FEV₁ reversibility (%)* | 16.3 (15,85) | 16.5 (16,27)

**Inclusion**
*   \- Aged ≥40 years
*   \- A smoking history of ≥10 pack yrs
*   \- A diagnosis of moderate-to-severe COPD (postbronchodilator 30≤FEV₁<65, FEV₁/FVC<0,7)

**Exclusion**
*   \- A history of asthma
*   \- History of exacerbation within the previous 6 weeks

**Intervention**
*   Indacaterol+tiotropium: Indacaterol 150 μg once daily, Tiotropium, 18 μg once daily
*   Placebo+tiotropium: Tiotropium, 18 μg once daily

### Result

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :----------------------- | :--------------------- | :----------------- |
| Number | 572 | 570 |

#### Differences between indacaterol+tio vs. tio+placebo

| Outcome | Value (95% CI) |
| :---------------------------- | :--------------- |
| FEV₁ AUC 5 min~8 h | 130 mL (90~160) |
| COPD severity - moderate | 110 mL (80~140) |
| COPD severity - severe | 140 mL (110~170) |
| Smoking status - ex smoker | 90 mL (50~120) |
| Smoking status - current smoker | 140 mL (100~170) |
| ICS use - non-users | 100 mL (70~140) |
| ICS use - users | |

#### Trough FEV₁

| Outcome | Value (95% CI) |
| :---------------------------- | :--------------- |
| COPD severity - moderate | 90 mL (60~120) |
| COPD severity - severe | 60 mL (30~90) |
| Smoking status - ex smoker | 80 mL (60~110) |
| Smoking status - current smoker | 60 mL (20~90) |
| ICS use - non-users | 90 mL (60~120) |
| ICS use - users | 60 mL (30~90) |

#### Patient reported symptoms and use of as-needed salbutamol

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :------------------------------------------ | :--------------------- | :----------------- |
| Change from baseline symptom score (full 24 h) | -2,2 (0,21) | -1,5 (0,21) |
| Change from baseline symptom score (day-time) | -1,1 (0,12) | -0,8 (0,12) |
| Change from baseline symptom score (night-time) | -1,0 (0,12) | -0,7 (0,12) |
| Change from baseline salbutamol use (puff/day) | -2,1 (0,17) | -1,4 (0,17) |
| Days during treatment with no salbutamol use (%) | 38,7 (1,94) | 33,6 (1,92) |

#### Adverse events (%)

| Outcome | Indacaterol+tiotropium | Placebo+tiotropium |
| :--------------------------- | :--------------------- | :----------------- |
| Cough | 9,1 | 4,4 |

<PAGE>123